Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study.  | Zenas Biopharma’s lead autoimmune drug ...

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo ... today announced positive results from the Phase 2 MoonStone trial of ...

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - ...

Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of ...

Takeda (TAK) announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab, an anti-CD38 monoclonal ...

Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch ...

Immunovant remains a high-risk, high-reward play, hinging on the success of its next-gen candidate IMVT-1402. Click to read my latest analysis of IMVT stock.

The third quarter 2025 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call and replay ...

Clinical results showed that for six months after discontinuing Batoclimab, about 80% of patients maintained normal thyroid ...

On October 29, HanAll Biopharma announced its provisional consolidated financial results for the third quarter of this year. The company reported ...

SC GD Medical Admit Card 2025: The Staff Selection Commission (SSC) has officially issued the admit card for the Medical Test ...

The State Bank of India (SBI) has announced the SBI PO Mains Result 2025 on its official website sbi.co.in. Candidates can download the result PDF, check roll numbers of shortlisted candidates, and ...